Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention
Objectives The aim of this work was to investigate the efficacy and safety of loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes ( NSTEACS ) undergoing elective percutaneous coronary intervention ( PCI ) . Methods A total of 126 patients ( ≥70 years old ) with NSTEACS were r and omly divided into two groups : ( 1 ) loading-dose rosuvastatin-treated group , treated with rosuvastatin 20 mg 12 h prior to PCI , with a second dose administered just before PCI ( n = 62 ) , and ( 2 ) control-treated group , treated with the st and ard method according to ACC/AHA guidelines in UAP/NSTEMI 2007 ( n = 64 ) . All patients were required to take rosuvastatin 10 mg once a day starting 24 h after the surgery irrespective of the initial r and omization assignment . The serum soluble lectin-like oxidized low-density lipoprotein receptor-1 ( sLox-1 ) , high-sensitivity C-reactive protein ( hs-CRP ) , creatinine kinase (CK)-MB , cardiac troponin I ( cTnI ) , and brain natriuretic peptide ( BNP ) levels were measured prior to PCI and at 24 h and 30 days after PCI in both groups . The left ventricular ejection fraction ( LVEF ) levels were recorded prior to PCI and 30 days after PCI in both groups . Results Compared to pre-PCI , the serum sLox-1 , hs-CRP , CK-MB , and cTnI levels were increased at 24 h after PCI ( all p < 0.05 ) in both groups . However , the increased sLox-1 , hs-CRP , CK-MB , and cTnI values were significantly lower in the loading-dose rosuvastatin-treated group than in the control-treated group ( p < 0.05 ) . In addition the serum sLox-1 and hs-CRP levels were lower in the loading-dose rosuvastatin-treated group than in the control-treated group at 30 days after PCI . However , the decreased values of sLox-1 and hs-CRP from 24 h after PCI to 30 days after PCI did not show any significant difference between the two groups . No significant difference was found in the serum ALT and Scr levels between the two groups before and after PCI . Compared to the control-treated group , the serum BNP level decreased ( p < 0.05 ) and LVEF ( p < 0.05 ) increased in the loading-dose rosuvastatin-treated group at 30 days after PCI . Conclusion The loading-dose rosuvastatin therapy in elderly patients with non-ST-segment elevation acute coronary syndromes undergoing elective PCI can attenuate the increase in serum hs-CRP , sLox-1 , CK-MB , and cTnI levels , reduce myocardial injury and inflammatory reaction caused by PCI , and improve the LVEF level at 30 days after PCI , ensuring an effective and safe therapy
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .